Tony's Publications and Lectures

  1. Continuing Education Series
  2. Publications
    1. Textbooks
    2. Textbook Chapters
    3. Refereed Articles
    4. Non-refereed Articles
  3. Presentations

 

Veterinary Oncology Consultants Continuing Education Series

Sept 2011 - Minicourse in Oncology for Veterinary Practitioners. Tamworth

Sept 2009 - Minicourse in Surgical Oncology for Veterinary Practitioners. Sydney/Port Macquarie

Jan 2009 - Minicourse in Oncology for Veterinary Practitioners. Kuala Lumpur, MALAYSIA

Oct 2008 - Minicourse in Oncology for Veterinary Practitioners. Canberra

Apr 2007 - Minicourse in Oncology for Veterinary Practitioners. Coogee Beach

Mar 2006 - Minicourse in Oncology for Veterinary Practitioners. Port Macquarie

 

Publications

Textbooks

Ogilvie GK, Moore AS.

Managing the Veterinary Cancer Patient: A Practice Manual. Veterinary Learning Systems (VLS Books). Trenton, NJ. 1995. ISBN 1-884254-20-9

 

Managing the Veterinary Cancer Patient: A Practice Manual.

Published in Japanese by LLL Seminar, Tokyo. 1995

 

Manuel Pratique de Cancerologie Veterinaire

Published in French by Masson Edition du Point Veterinaire, Paris. 1997. ISBN 2-225-85451-3

 

Ogilvie GK, Moore AS: Feline Oncology: A Comprehensive Guide to Compassionate Care. Veterinary Learning Systems (VLS Books). Trenton, NJ, 2001. ISBN 1-884254-53-5

 

Feline Oncology: A Comprehensive Guide to Compassionate Care. Published in Japanese by Interzoo, Tokyo. 2003. ISBN 4-89995-253-8

 

Ogilvie GK, Moore AS: Managing the Canine Cancer Patient: A Practical Guide to Compassionate Care. Veterinary Learning Systems (VLS Books). Yardley, PA, 2006. ISBN 1-884254-56-X

 

Managing the Canine Cancer Patient: A Practical Guide to Compassionate Care.

Published in Japanese by Interzoo, Tokyo. 2008. ISBN 978-4-89995-428-6

 

Moore AS, Frimberger AE: Oncology for Veterinary Technicians and Nurses. Wiley-Blackwell. Ames, IA, 2009. ISBN: 978-0-8138-1276-2

 

Textbook Chapters

14 Frimberger AE, Moore AS. Principles and Practice of Chemotherapy.

Textbook Of Veterinary Internal Medicine Eighth Edition (SJ Ettinger, EC Feldman and E Côté eds) Elsevier Science. Philadelphia. 2015.

 

13 Oncology Section Editor. August's Consultations in Feline Internal Medicine. Volume 7, 2015

 

12 Moore AS. Malignant Effusions. Chapter 75. In: Current Veterinary Therapy XV. Small Animal Practice (JD Bonagura, DC Twedt eds) Elsevier, St Louis MO. 341-344, 2014.

 

11 Moore AS. Neoplasia of the oral cavity and salivary glands. In: Canine and Feline Gastroenterology (RJ Washabau, MJ Day eds) Elsevier, St Louis MO. 553-559, 2012.

 

10 Moore AS. Practical Chemotherapy.

Textbook Of Veterinary Internal Medicine Seventh Edition (SJ Ettinger and EC Feldman eds) Elsevier Science. Philadelphia. 2126-2132, 2010.

 

9 Moore AS, Frimberger AE. Anticancer drugs and protocols - Traditional. In: Current Veterinary Therapy XIV. Small Animal Practice (RW Kirk, JD Bonagura eds) Elsevier, St Louis MO. 305-311, 2008.

 

8 Moore AS. Practical Chemotherapy.

Textbook Of Veterinary Internal Medicine Sixth Edition (SJ Ettinger and EC Feldman eds) Elselvier Science. Philadelphia. 713-720, 2005.

 

7 Moore AS, Kitchell BE. New chemotherapy drugs in veterinary medicine.

Veterinary Clinics of North America: Small Animal Practice. Update in Medical Oncology.

Elselvier Science. Philadelphia. 33: 629-649, 2003.

 

6 Moore AS, Frimberger AE. Principles of Chemotherapy.

Textbook Of Veterinary Internal Medicine Fifth Edition (SJ Ettinger and EC Feldman eds) WB Saunders Co., Philadelphia. 484-489, 1999.

 

5 Moore AS, Mahony O. Treatment of Feline Malignant Lymphoma. In: Current Veterinary Therapy XII. Small Animal Practice (RW Kirk, JD Bonagura eds) WB Saunders, Philadelphia. 498-502, 1995.

 

4 Moore AS. Treatment of Cancer in Companion Animals. University of Sydney Postgraduate Committee in Veterinary Science, Proceedings 224, 1994.

 

3 Leveille C, Moore AS. Multiple Drug Resistance.

Advances Vet Science Compar Med 37 31-59, 1993.

 

2 Moore AS. Chemotherapy for intrathoracic cancer in dogs and cats.

Problems in Veterinary Medicine 4 351-364, 1992.

 

1 Ogilvie GK, Moore AS. Mitoxantrone chemotherapy in small animals. In: Current Veterinary Therapy XI. Small Animal Practice (RW Kirk, JD Bonagura eds) WB Saunders, Philadelphia. 399-402, 1992.

 

Refereed Articles

99 Chemotherapy Trials in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease

Phalen DN, Frimberger A, Stephen Pyecroft P, Peck S, Harmsen C, Lola S, Moore AS. In progress

98 George R, Smith A, Schleis S, Brawner W, Almond G, Kent M, Wypij J, Borrego JF, Moore A, Keyerleber M, Cadile C, Kraiza S, Hamilton T, Arthur J. Survival of Dogs with Intranasal Lymphoma Treated with Various Radiation Protocols: 27 cases. In progress

97 Moore AS, Reppas G, Taylor D, Frimberger AE. Histologic and immunohistochemical review of non-visceral histiocytic sarcomas in dogs. In progress.

96 Goodman IH, Moore AS, Frimberger AE. Treatment of canine multicentric non-indolent T-cell lymphoma using VELCAP-TSC protocol: 72 cases (2003-2013). JAVMA submitted Mar 2015.

95 Tran CM, Moore AS, Frimberger AE. Surgical treatment of mammary carcinomas in dogs with or without postoperative chemotherapy. Veterinary Comparative Oncol : DOI: 10.1111/vco.12092

94 Frimberger AE, Tran CM, Moore AS. Canine osteosarcoma treated by post-amputation sequential accelerated doxorubicin and carboplatin chemotherapy: 38 Cases. J Am An Hosp Assoc in press

93 Moore AS. Extranodal lymphoma in cats: prognostic factors and treatment options. Journal Feline Med Surg 15 379-390, 2013.

92 Phalen DN, Frimberger AE, Pyecroft S, Peck S, Harmsen C, Lola S, de Mello Mattos B, Li KM, McLachlan A, Moore AS. Vincristine Chemotherapy Trials and Pharmacokinetics in Tasmanian Devils with Tasmanian Devil Facial Tumor Disease. PLoS.One 2013.
http://dx.plos.org/10.1371/journal.pone.0065133.

91 Moore AS, Frimberger AE, Sullivan N, Moore PF. Histologic and immunohistochemical review of splenic fibrohistiocytic nodules in dogs. J Vet Internal Med 26:1164-1168, 2012.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2012.00986.x/epdf

90 Takashima-Uebelhoer BB, Barber LG, Zagarins SE, Procter-Gray E, Gollenberg AL, Moore AS, Bertone-Johnson ER. Household Chemical Exposures and the Risk of Canine Malignant Lymphoma,

a Model for Human Non-Hodgkin’s Lymphoma. Environmental Research 112:171-176, 2012.

89 Webster JD, Dennis MM, Dervisis N, Heller J, Bacon NJ, Bergman PJ, Bienzle D, Cassali G, Castagnaro M, Cullen J, Esplin DG, Peña L, Goldschmidt MH, Hahn KA, Henry CJ, Hellmén E, Kamstock D, Kirpensteijn J, Kitchell BE, Amorim RL, Lenz SD, Lipscomb TP, McEntee M, McGill LD, McKnight CA, McManus PM, Moore AS, Moore PF, Moroff SD, Nakayama H, Northrup NC, Sarli G, Scase T, Sorenmo K, Schulman FY, Shoieb AM, Smedley RC, Spangler WL, Teske E, Thamm DH, Valli VE, Vernau W, von Euler H, Withrow SJ, Weisbrode SE, Yager J, Kiupel M. Recommended Guidelines for the Conduct and Evaluation of Prognostic Studies in Veterinary Oncology. Vet Pathol 48 7-18, 2011

88 Moore AS. Managing cats with cancer: an examination of ethical perspectives. Journal Feline Med Surg 13 661–671, 2011.

87 Rassnick K, Moore AS, Russell D, Northrup N, Kristal O, Bailey D, Flory A, Kiselow M, Intile J. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma. J Vet Internal Med 24 1528-1531, 2010.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2010.0588.x/epdf

86 Moore AS. Treatment choices for oral cancer in cats. What is possible? What is reasonable? Journal Feline Med Surg 11 23-31, 2009.

85 Rassnick KM, Moore AS, Collister KE, Northrup NC, Kristal O, Chretin JD, Bailey DB. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs. . J Vet Internal Med 23 317-322, 2009.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2008.0270.x/epdf

84 Lingard AE, Beatty JA, Moore AS, Krockenberger M, Crowley AM, Churcher RK, Briscoe K, Barrs V. Diffuse alimentary lymphoma: clinicopathologic findings and response to treatment in 19 cases. Journal Feline Med Surg 11 692-700, 2009.

83 Hadden AG, Moore AS, Cotter SM, Rand WM, Davis RM, Morrissey P. Efficacy and toxicity of VELCAP-C chemotherapy for feline lymphoma. J Vet Internal Med 22 153-157, 2008.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2007.0031.x/epdf

82 Moore AS, Dernell WS, Ogilvie GK, Kristal O, Elmslie R, Kitchell B, Susaneck S, Rosenthal R, Klein MK, Obradovich J, Legendre A, Haddad T, Hahn K, Powers BE, Warren D. Doxorubicin and Bay-129566 for the Treatment of Osteosarcoma in Dogs: A Randomized, Double Blind, Placebo Controlled Study. J Vet Internal Med 21 783-790, 2007.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2007.tb03022.x/epdf

81 Barnard SM, Zuber RM, Moore AS. The use of 153Samarium-EDTMP in the palliation of primary bone tumors in dogs: a retrospective study of 35 cases. J Am Vet Med Assoc 203 1877-1881, 2007.

80 Ogilvie GK, Moore AS. Oncologic pain in dogs: prevention and treatment. Compendium on Continuing Education for the Practicing Veterinarian 28, 2006.

79 Ogilvie GK, Moore AS. Oncologic pain: concepts and assessment. Compendium on Continuing Education for the Practicing Veterinarian 28 707-713, 2006.

78 Brown EM, Ruslander DM, Azuma C, Moore AS, Bengtson AE, Quesenberry PJ, Frimberger AE. A feasibility study of low dose total body irradiation for relapsed canine lymphoma. Veterinary and Comparative Oncology 4, 75-83, 2006

77 Chretin JD, Shaw NA, Hahn KA, Ogilvie GK, Kristal O, Northrup NC, Rassnick KM, Moore AS. Reduced morbidity following prophylactic trimethoprim-sulfadiazine administration during chemotherapeutic induction: a double-blind placebo-controlled study J Vet Internal Med 21, 141-148, 2007
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2007.tb02940.x/epdf

76 Simon D, Ruslander DM, Rassnick KM, Wood CA, A.E. Frimberger AE, Cotter SM, King NW, Moore AS. Orthovoltage radiation and weekly low dose of doxorubicin for the treatment of incompletely excised soft-tissue sarcomas in 39 dogs Vet Record 160, 321-326, 2007.

75 Rassnick KM, Moore AS, Northrup NC, Kristal O, Beaulieu BB, Lewis LD, Page RL. Phase I and pharmacokinetic study of ifosfamide in cats with soft tissue sarcomas. Am J Vet Research 67, 510-516, 2006

74 Frimberger AE, Moore AS, Rassnick KM, Cotter SM, O’Sullivan JL, Quesenberry PJ. A combination chemotherapy protocol with dose intensification and autologous bone marrow transplant (VELCAP-HDC) for canine lymphoma. J Vet Internal Med 20, 355-364, 2006
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2006.tb02868.x/epdf

73 MacGregor JM, Faria MLE, Moore AS, Tobias AH, Brown DJ, Morais HSA. Cardiac lymphoma and pericardial effusion in dogs: 12 Cases (1994-2004). J Am Vet Med Assoc 227, 1449-1453, 2005.

72 Cahalane AK, Payne S, Barber LG, Duda LE, Henry CJ, Mauldin GE, Frimberger AE, Cotter SM, Moore AS. Prognostic factors for survival of dogs with inguinal and perineal mast cell tumors treated surgically with or without adjunctive treatment: 68 cases (1994-2002). J Am Vet Med Assoc 225, 401-408, 2004

71 Payne SE, Rassnick KM, Northrup NC, Kristal O, Chretin JD, Cotter SM, Kintzer P, Frimberger AE, Morrison-Collister KE, Wood CA, Moore AS. Treatment of vascular and soft-tissue sarcomas in dogs using an alternating protocol of ifosfamide and doxorubicin. Veterinary and Comparative Oncology 1, 171-179, 2004

70 Morrison-Collister KE, Rassnick KM, Northrup NC, Kristal O, Chretin JD, Williams LE, Cotter SM, Moore AS. A combination chemotherapy protocol with MOPP and CCNU consolidation (Tufts VELCAP-SC) for the treatment of canine lymphoma. Veterinary and Comparative Oncology 1, 180-190, 2004

69 Snyder LA, Bertone ER, Dooner MS, Jennings J, Jakowski R, Moore AS. P53 expression and environmental tobacco smoke exposure in feline oral squamous cell carcinoma. Veterinary Pathology 41,209-214, 2004

68 Kristal O, Rassnick KM, Gliatto JM, Northrup NC, Chretin JD, Morrison-Collister K, Cotter SM, Moore AS, Hepatotoxicity associated with CCNU (Lomustine) chemotherapy in dogs. J Vet Internal Med 18, 75-80, 2004
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2004.tb00138.x/epdf

67 Williams LE, Gliatto JM, Dodge RK, Gamblin RM, Thamm DH, Lana SE, Szymkowski M, Moore AS. Canine carcinoma of the apocrine glands of the anal sac: 113 cases (1985-1995). J Am Vet Med Assoc 223,825-831, 2003

66 Beam SL, Rassnick KM, Moore AS, McDonough SP. An immunohistochemical study of cyclooxygenase-2 expression in various feline neoplasms. Veterinary Pathology 40, 496-500, 2003

65 Moore AS, deSouza PL, Imondi AR, Wood CA. Intravenous administration of 9-aminocamptothecin (9-AC) to dogs with lymphoma. Veterinary and Comparative Oncology 1, 86-93, 2003

64 Moore AS, Beam SL, Rassnick KM, Provost PJ. Long-term control of mucocutaneous squamous cell carcinoma and metastases in a horse using piroxicam. Equine Veterinary Journal 35, 715-718, 2003

63 Penninck D, Smyers B, Leveille-Webster CR, Rand W, Moore AS. Diagnostic value of ultrasonography in differentiating enteritis from intestinal neoplasia in dogs. Vet Radiology and Ultrasound 44, 570-575, 2003

62 Bertone ER, Snyder LA, Moore AS. Risk factors for oral squamous cell carcinoma in cats. J Vet Internal Med 17, 557-562, 2003.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2003.tb02478.x/epdf

61 DeRegis CJ, Moore AS, Rand WM, Berg J. Toxicity in 100 dogs with osteosarcoma after combination chemotherapy with cisplatin and doxorubicin. J Vet Internal Med 17, 668-673, 2003
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2003.tb02498.x/epdf

60 Clancy EA, Moore AS, Bertone ER. Feline and owner characteristics and outdoor access of owned cats. J Am Vet Med Assoc 222, 1541-1545, 2003.

59 Moore AS, Nelson RW, Henry CJ, Rassnick KM, Kristal O, Ogilvie GK, Kintzer P. Streptozocin for treatment of pancreatic islet cell tumors in dogs: 17 cases (1989-1999). J Am Vet Med Assoc 221, 811-818, 2002.

58 Moore AS. Radiation therapy for the treatment of tumours in small companion animals. The Veterinary Journal 164, 176-187, 2002.

57 Rassnick KM, Mauldin GE, Al-Sarraf R, Mauldin GN, Moore AS, and Mooney SC. MOPP chemotherapy for treatment of resistant lymphoma in dogs: a retrospective study of 117 cases (1989-2000) J Vet Internal Med 16, 576-580, 2002.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2002.tb02390.x/epdf

56 Bertone ER, Snyder LA, Moore AS. Environmental tobacco smoke and risk of malignant lymphoma in pet cats. Am J Epidemiology 156, 268-273, 2002.

55 Paoloni MC, Penninck DG, Moore AS. Ultrasonographic and clinicopathologic findings in 21 dogs with intestinal adenocarcinoma. Vet Radiology and Ultrasound 43, 562-567, 2002.

54 Northrup NC, Rassnick KM, Snyder LA, Kristal O, Cotter SM, Moore AS. Neutropenia associated with vincristine and Lasparaginase induction chemotherapy for canine lymphoma. J Vet Internal Med 16, 570-575, 2002.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2002.tb02389.x/epdf

53 Ogilvie GK, Moore AS. Endocrine manifestations of malignancy in cats. Compendium on Continuing Education for the Practicing Veterinarian 23 1042-1048, 2001.

52 Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, Meleo KA, Moore AS. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). J Am Vet Med Assoc 218 1444-1448, 2001.

51 Rassnick KM, Geiger TL, Williams LE, Ruslander DM, Northrup NC, Kristal O, Myers NC, Moore AS. Phase I evaluation of CCNU (lomustine) in tumor-bearing cats. J Vet Internal Med 15 196-199, 2001.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2001.tb02311.x/epdf

50 Moore AS. Osteosarcoma in dogs: managing a destructive disorder. Veterinary Medicine 161 539-546, 2001.

49 Kristal O, Lana SE, Ogilvie GK, Cotter SM, Moore AS. Single agent chemotherapy with doxorubicin for feline lymphoma. J Vet Internal Med 15 125-130, 2001.

48 Northrup NC, Etue S, Ruslander D, Rassnick KM, Hutto DL, Bengston A, Rand W, Moore AS. Retrospective study of orthovoltage radiation for nasal tumors in 42 dogs. J Vet Internal Med 15 183-189, 2001.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2001.tb02309.x/epdf

47 Moore AS, Cotter SM, Rand WM, Wood CA, Williams LE, London CA, Frimberger AE, Gliatto J, L’Heureux DA. Evaluation of a discontinuous treatment protocol (VELCAP-S) for canine lymphoma. J Vet Internal Med 15 348-354, 2001
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2001.tb02328.x/epdf

46 Luna LD, Henry CJ, Higginbotham ML, Turnquist SE, Moore AS, Graham JC. Feline non-ocular melanoma: a retrospective study of 23 cases. (1991-1999). J Feline Med Surg 4 173-181, 2000.

45 Moore AS, Wood CA, Engler SJ, Bengtson AE. Radiation therapy for long-term control of odontogenic tumours and epulis in three cats. J Feline Med Surg 2 57-60, 2000.

44 Valli VE, Jacobs RM, Norris A, Couto CG, Morrison WB, McCaw D, Cotter SM, Ogilvie GK, Moore A. The histologic classification of 602 cases of feline lymphoproliferative disease using the National Cancer Institute working formulation. J Vet Diagnostic Investigation 12 295-306, 2000.

43 Rassnick KM, Frimberger AE, Wood CA, Williams LE, Cotter SM, Moore AS. Evaluation of ifosfamide for treatment of various canine neoplasms. J Vet Internal Med 14 271-276, 2000.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2000.tb01166.x/epdf

42 Burgess K, Moore AS, Rand WM, Cotter SM. Immune mediated hemolytic anemia in dogs: a retrospective study of 60 cases treated with cyclophosphamide (1989-1994). J Vet Internal Med 14 456-462, 2000.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.2000.tb02256.x/epdf

41 Rassnick KM, Moore AS, Williams LE, London CA, Kintzer PP, Cotter SM. Treatment of canine mast cell tumors with CCNU. J Vet Internal Med 13 601-605, 1999.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1999.tb02217.x/epdf

40 Moore AS, London CA, Wood CA, Williams LE, Cotter SM, L'Heureux DA, Frimberger AE. Lomustine (CCNU) for the treatment of relapsed lymphoma in dogs. J Vet Internal Med 13 395-398, 1999.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1999.tb01452.x/epdf

39 Moore AS. Advances in the treatment of canine and feline lymphoma. Modern Veterinary Medicine 8 (42) 6-13, 1999

38 Frimberger AE, Moore AS, Cincotta L, Cotter SM, Foley JW. Photodynamic therapy of naturally occurring tumors in animals using a novel benzophenothiazine photosensitizer. Clin. Cancer Research 4 2207-2218, 1998.

37 Kelsey J, Moore AS, Glickman LT. Epidemiologic studies of risk factors for cancer in pet dogs. Epidemiologic Reviews 20 204-217, 1998.

36 Zemann B, Moore AS, Rand WM, Mason G, Ruslander DM, Frimberger AE, Wood CA, L'Heureux DA, Gliatto J, Cotter SM. A combination chemotherapy protocol (VELCAP-L) for dogs with lymphoma.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1998.tb02151.x/epdf

J Vet Internal Med 12 465-470, 1998.

35 Albers TM, Alroy J, McDonnell JJ, Moore AS. A poorly differentiated gastric carcinoid in a dog.

J Vet Diagn. Invest. 10 116-118, 1998

34 Wood CA, Moore AS, Gliatto JG, Ablin LA, Berg RJ, Rand WM. Prognosis for dogs with stage I or II splenic hemangiosarcoma treated by splenectomy alone: 32 cases (1991-1993). J Am Anim Hosp Assoc 34 417-421, 1998.

33 Vail DM, Moore AS, Ogilvie GK, Volk LM. Feline lymphoma (145 cases): proliferation indices, Cluster of Differentiation 3 immunoreactivity and their association with prognosis in 90 cats receiving therapy.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1998.tb02134.x/epdf

J Vet Internal Med 12 349-354, 1998.

32 Penninck DG, Moore AS, Gliatto JM. Ultrasonography of canine gastric epithelial neoplasia.

Vet Radiology and Ultrasound 39 342-348, 1998

31 Myers NC, Moore AS, Rand WM, Gliatto J, Cotter SM. Evaluation of a multidrug chemotherapy protocol (ACOPA II) in dogs with lymphoma. J Vet Internal Med 11 333-339, 1998
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1997.tb00476.x/epdf

30 McCaw DL, Miller MA, Bergman P, Withrow SJ, Moore AS, Knapp DW, Fowler D, Johnson JC. Vincristine therapy for canine mast cell tumors. J Vet Internal Med 11 375-378, 1998
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1997.tb00484.x/epdf

29 Frimberger AE, Moore AS, LaRue SM, Gliatto JM, Bengtson A. Prognosis for dogs with intermediately differentiated mast cell tumors treated with surgery and orthovoltage or linear accelerator radiation therapy: 40 cases (1990-1994). J Amer Animal Hosp Assoc 33 320-324, 1997.

28 Moore AS, Cotter SM, Frimberger AE, Wood CA, L'Heureux DA. A comparison of doxorubicin vs. COP for maintenance of remission in cats treated for lymphoma. J Vet Internal Med 10 372-375, 1996.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1996.tb02083.x/epdf

27 Moore AS. Treatment of feline lymphoma. Feline Practice 24 (6) 17-20, 1996.

26 Mahony OM, Moore AS, Cotter SM, Engler SJ, Penninck DG. Alimentary lymphoma in cats: 28 cases (1988-1993). J Am Vet Med Assoc 207 1593-1598, 1995.

25 Pirkey-Ehrhart N, Withrow SJ, Straw RC, Ehrhart EJ, Page RL, Hottinger HL, Hahn KA, Morrison WB, Albrecht MR, Hedlund CS, Hammer AS, Holmberg DL, Moore AS, King RR, Klausner JS. Primary rib tumors in 54 dogs. J Am Anim Hosp Assoc 31 65-69, 1995.

24 Frimberger AE, Moore AS. Treatment of nephroblastoma in a juvenile Bernese Mountain Dog. A case report. J Am Vet Med Assoc 207 596-598, 1995.

23 Moore AS, Leveille CR, Reimann KA, Shu H, Arias IM. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Cancer Investigation 13 475-479, 1995.

22 Moore AS, Ruslander D, Cotter SM, Rand WM, L'Heureux DA. Efficacy of and toxicoses associated with oral idarubicin administration in cats with neoplasia. J Am Vet Med Assoc 206 1550-1554, 1995.

21 Ogilvie GK, Moore AS, Chen C, Ciekot PA, Atwater SW, Bergman PA, Walters LM. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors: a dose escalation study. J Am Vet Med Assoc 205 570-573, 1994.

20 Moore AS, Ogilvie GK, Vail DM. Actinomycin D for reinduction of remission in dogs with resistant lymphoma. J Vet Internal Med 8 343-344, 1994.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1994.tb03247.x/epdf

19 Watson ADJ, Moore AS, Helfand SC. Primary erythrocytosis in the cat: treatment with hydroxyurea. J Small Anim Pract 35 320-325, 1994.

18 Penninck DG, Moore AS, Tidwell AS, Matz ME, Freden GO. Ultrasonography of alimentary lymphosarcoma in the cat. Vet Radiol 35 299-304, 1994.

17 Moore AS, Rand WM, Berg J, L'Heureux DA, Dennis RA. Evaluation of butorphanol and cyproheptadine for prevention of cisplatin-induced vomiting in dogs. J Am Vet Med Assoc 205 441-443, 1994.

16 Moore AS, Ogilvie GK, Ruslander D, Rand WS, Cotter SM, Getzy DM, L'Heureux DA, Dennis RA. Evaluation of mitoxantrone for the treatment of lymphoma in dogs. J Am Vet Med Assoc 204 1903-1905, 1994.

15 Ruslander D, Moore AS, Gliatto JM, L'Heureux D, Cotter SM. Cytosine arabinoside as a single agent for the induction of remission in canine lymphoma. J Vet Internal Med 8 299-301, 1994.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1994.tb03237.x/epdf

14 Moore AS. Recent advances in chemotherapy for non-lymphoid malignancies. Compend Contin Educ Pract Veterinarian. 15 1039-1052, 1993.

13 Ogilvie GK, Moore AS, Obradovich JE, Elmslie RE, Vail DM, Straw RC, Salmon MD, Klein MK, Atwater SW, Ciekot PE, LaRue SM, Peaston A, Withrow SJ. Toxicoses and efficacy associated with administration of mitoxantrone to cats with malignant tumors. J Am Vet Med Assoc 202 1839-1844, 1993.

12 Spodnick GJ, Berg RJ, Rand WM, Schelling SH, Couto G, Harvey HJ, Henderson RA, MacEwen G, Mauldin N, McCaw DL, Moore AS, Morrison W, Norris AM, O'Bradovich J, O'Keefe DA, Page R, Ruslander D, Klausner J, Straw R, Thompson JP, Withrow SJ. Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). J Am Vet Med Assoc 200 995-999, 1992.

11 Theon AP, Madewell BR, Moore AS, Stephens C, Krag DN. Localized thermo-cisplatin therapy: a pilot study in spontaneous canine and feline tumours. Int J Hyperthermia 7 881-892, 1991.

10 Moore AS, Kirk C, Cardona A; Intracavitary cisplatin chemotherapy: experience with six dogs.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1991.tb00953.x/epdf

J Vet Internal Med 5 227-231, 1991.

9 Moore AS, Theilen GH, Newell AD, Madewell BR, Rudolf AR. Preclinical study of sequential tumor necrosis factor and interleukin 2 in the treatment of spontaneous canine neoplasms. Cancer Research 51 233-238, 1991.

8 Ogilvie GK, Obradovich JE, Elmslie RE, Vail DM, Moore AS, Straw RC, Dickinson K, Cooper MF, Withrow SJ. Efficacy of mitoxantrone against various neoplasms in dogs. J Am Vet Med Assoc 198 1618-1621, 1991

7 Ogilvie GK, Obradovich JE, Elmslie RE, Vail DM, Moore AS, Curtis CR, Straw RC, Dickinson K, Cooper MF, Withrow SJ. Toxicoses associated with the administration of mitoxantrone to dogs with malignant tumors. J Am Vet Med Assoc 198 1613-1617, 1991

6 Moore AS, Cardona A, Madewell BR; Cisplatin (cisdiammine dichloroplatinum) for treatment of transitional cell carcinoma of the urinary bladder or urethra; a retrospective study of 15 dogs.
http://onlinelibrary.wiley.com/doi/10.1111/j.1939-1676.1990.tb00888.x/epdf

J Vet Internal Med 4 148-156, 1990.

5 Moore AS, Madewell BR, Cardinet III GH, Shelton GD: Osteogenic sarcoma and myasthenia gravis in a dog. J Am Vet Med Assoc 197 226-227, 1990.

4 Ogilvie GK, Moore AS, Curtis CR; Evaluation of cisplatin induced emesis in dogs with malignant neoplasia: 115 cases (1984-1987). J Am Vet Med Assoc 195 1399-1403, 1989.

3 Moore AS, Madewell BR, Lund JK; The immunohistochemical evaluation of intermediate filament expression in canine and feline neoplasms. Amer J Vet Research 50 88-92, 1989.

2 Middleton DJ, Moore AS, Medhurst CJ; Haemobartonellosis in a dog. Australian Vet J 59 29-30, 1982.

1 Moore AS, Middleton DJ; Pulmonary adenocarcinoma in three cats with non-respiratory signs only.

J Small Animal Practice 23 501-509, 1982.

 

 

Non-refereed Articles

The Veterinarian March 2015. 23-28.

Frimberger AE, Moore AS. Canine urinary tract transitional cell carcinoma.

 

The Veterinarian December 2014. 21-25.

Frimberger AE, Moore AS. The marrow madness of cats: classifying feline myelodysplastic syndromes and leukemias.

 

The Veterinarian August 2014. 17-19.

Moore AS, Frimberger AE. Epitheliotropic T-cell lymphoma in dogs.

 

The Veterinarian March 2014. 29-33.

Moore AS, Frimberger AE. Treatment of feline lymphoma.

 

Japanese Journal of Veterinary Clinical Oncology. 9 (2) 8-15, 2013.

Moore AS. Insulinoma in dogs : new treatments. (In Japanese)

 

Japanese Journal of Veterinary Clinical Oncology. 9 (2) 44-47, 2013.

Moore AS. Progress in Veterinary Oncology. (In Japanese)

 

The Veterinarian August 2013. 19-24.

Moore AS, Frimberger AE. Advances in care for canine lymphoma.

 

The Veterinarian August 2012. 23-27.

Moore AS, Frimberger AE. Splenic haemangiosarcoma in dogs: prognosis and treatment.

 

The Veterinarian May 2012.

Moore AS, Frimberger AE. Oral tumours in cats.

 

The Veterinarian February 2012. 23-27.

Frimberger AE, Moore AS. The new and increasing role of tyrosine kinase inhibitors in veterinary oncology: masitinib (Masivet) and toceranib (Palladia).

 

The Veterinarian August 2011.

Moore AS, Frimberger AE. Canine melanoma; treatment options for a difficult disease.

 

The Veterinarian July 2011. 37-41.

Moore AS, Frimberger AE. Understanding the histiocytic diseases in dogs.

 

The Veterinarian March 2011, 19-23.

Frimberger AE, Moore AS. Chemotherapy preparation & administration safety issues in veterinarian medicine.

 

The Veterinarian December 2010. 23-28.

Moore AS, Frimberger AE. When a mediastinal mass is not lymphoma: thymoma in dogs and cats.

 

The Veterinarian August 2010.

Moore AS, Frimberger AE. An interpretive summary of 9 commonly used anticancer chemotherapy drugs.

 

The Veterinarian April 2010.

Frimberger AE, Moore AS. Haematopoietic stem cell transplantation in veterinary medicine.

 

The Veterinarian July 2009.

Frimberger AE, Moore AS. A Clinical Oncology Perspective on the Use of Serum Biochemistry Analysis, Urinalysis, & Ancillary Tests in Cancer Patients

 

The Veterinarian Feb 2009.

Frimberger AE, Moore AS. Mammary carcinomas in dogs.

 

The Veterinarian Oct 2008 23-26.

Frimberger AE, Moore AS. Staging for dogs and cats with cancer (why should I run all those tests?).

 

The Veterinarian July 2008 37-43.

Moore AS, Frimberger AE, Reppas G, Carrigan M. An oncologist’s perspective of the pathologist’s role in cancer management.

 

The Veterinarian May 2008.

Frimberger AE, Moore AS. Managing Chemotherapy Patients in Private Practice

 

The Veterinarian Feb 2008 57-63.

Frimberger AE, Moore AS. Radiation therapy: clinical uses and outcomes.

Reprinted updated in March 2015 20-24 as Radiation therapy: conventional clinical uses and outcomes

 

The Veterinarian Nov 2007 45-51.

Moore AS. Equine sarcoids: recent advances in approaches to treatment.

 

The Veterinarian May 2007 43-48.

Moore AS, Frimberger AE. Radiation therapy: principles and side effects.

 

Standards of Care: Emergency and Critical Care Medicine. 9 (4) 9-11, 2007.

Ogilvie GK, Moore AS. Malignancy associated hypoglycemia in dogs.

 

The Veterinarian Feb 2007 33,35.

Frimberger AE, Moore AS. How to treat the neutropenic chemotherapy patient.

 

The Veterinarian 2006

Moore AS. Environmental causes of Cancer in Pets

 

Japanese Journal of Veterinary Clinical Oncology. 1 (1) 20-25, 2005.

Moore AS. Lymphoma in dogs: A review of protocols at Tufts University from 1977-2001

 

Veterinary Forum. December 40-46, 2006.

Ogilvie GK, Moore AS. Critical issues in senior pets: disease prevention, health and wellness.

 

Standards of Care: Emergency and Critical Care Medicine. 8 (8) 9-11, 2006.

Ogilvie GK, Moore AS. Cancer cachexia as a manifestation of malignancy.

 

Standards of Care: Emergency and Critical Care Medicine. 8 (4) 10-11, 2006.

Ogilvie GK, Moore AS. Anemia as a manifestation of malignancy.

 

Capsules: Lymphoma risk by canine breed. NAVC Clinician’s Brief. 4 (2) 39, 2006

 

The Veterinarian January 2006 29-32

Moore AS, Frimberger AE. Lymphoma in Dogs and the Evolution of Chemotherapy Protocols

 

Veterinary Technician. 27 92-96, 2006.

Ogilvie GK, Moore AS. Philosophy of Cancer Care.

 

Standards of Care: Emergency and Critical Care Medicine. 4(11):1–8, 2002.

Ogilvie GK, Moore AS. Neutropenia, sepsis, and thrombocytopenia in cats with cancer.

 

Standards of Care: Emergency and Critical Care Medicine. 2002.

Ogilvie GK, Moore AS. Chemotherapy-induced acute renal failure in cats.

 

Veterinary Technician. 22 114-119, 2001.

Morrissey P, Moore A. Invaded! Canine lymphoma.

 

Standards of Care: Emergency and Critical Care Medicine. 1 (6) 5-9, 1999.

Ogilvie GK, Moore AS. Vaccine/injection associated sarcomas.

 

Japan Veterinary Cancer Society Newsletter 3 (2) 41-44, 1998. Management of canine and feline mast cell tumors

 

Vet Cancer Soc Newsletter 20 (1) 9-10, 1996. Psycho-babble: The veterinary oncologist as a leader.

 

Advances in Small Animal Medicine and Surgery 8(4) 2-4, 1995. Comments on "Rescue therapy for lymphosarcoma".

 

Veterinary Digest 1 9-11, 1995. Evaluation of mitoxantrone for the treatment of lymphoma in dogs.

 

Tufts University School of Vet Med Imaging Newsletter 1 (7),1994. Radiation Therapy.

 

Treatment of Cancer in Companion Animals. Proceedings 224.

ISBN 1 875582 35 5

Post Graduate Committee in Veterinary Science.

University of Sydney. February 14-18, 1994.

Neoplastic processes. Pages 1-3.

Chemotherapy drug handling. Pages 11-18.

Canine lymphoma. Pages 37-65.

Feline lymphoma. Pages 67-73.

Radiation therapy. Pages 83-96.

Chemotherapy for non-lymphoid malignancies. Pages 111-129.

Chemotherapy toxicity. Pages 137-142.

Endocrine tumours. Pages 143-150.

Urinary tract tumours. Pages 159-161.

Alternative imaging for cancer staging. Pages 181-184.

Tumours of skin and adnexae. Pages 197-217.

Paraneoplastic diseases. Pages 253-258.

 

Vet Cancer Soc Newsletter 15 (1) 20, 1991. Mitoxantrone for the therapy of lymphoma.

 

Vet Cancer Soc Newsletter 14 (3) 8, 1991. Orally administered idarubicin.

 

Vet Cancer Soc Newsletter 12 (3) 6, 1988. Tumor necrosis factor as a cellular differentiating agent.

 

 

Presentations

June 2014 ACVIM Forum Scientific Sessions: Oncology : 1 hour.

T-cell lymphoma in dogs

32nd Annual ACVIM Veterinary Medical Forum, 2014.

 

June 2013 ACVIM Forum Scientific Sessions: Oncology : 1 hour.

Chemotherapy for malignant mammary carcinoma (405-407)

ACVIM Forum Veterinary Technician Sessions : Oncology : 1 hour.

Chemotherapy options for carcinomas and sarcomas in pets (835-837)

31st Annual ACVIM Veterinary Medical Forum, 2013.

 

Apr 2013 Cape Town, South Africa : 6 hours

Didma Conference Centre, South Africa : 12 hours

National Veterinary Clinicians Group of South Africa Conference

 

Jan 2013 Invited Keynote Speaker : 2 hours

Insulinoma: new treatments.

Progress in Veterinary Oncology

Japanese Veterinary Cancer Society, 8th Annual Conference, Tokyo, Japan

 

Jan 2013 New Perspectives on Lymphoma: practitioners in Tokyo, Japan

 

June 2011 ACVIM Forum Scientific Sessions : Oncology : 2 hours.

Feline Lymphoma: Time for a New Paradigm?

Devil Facial Tumor Disease: Biology, Epidemiology & Treatment Outcomes

29th Annual ACVIM Veterinary Medical Forum, 2011.

 

Nov 2010 Invited lecturer 1.0 hours

Practical tips for treating your cancer patients effectively and compassionately

Veterinary Pharmacology Symposium 2010; Brisbane, Australia

 

Sept 2010 Invited lecturer and Invited Keynote Speaker 3.0 hours

Epidemiology of feline cancers

Mammary cancer in cats

Treatment of feline lymphoma: ISFM Award Lecture.

ECVIM Congress 2010; ESFM/ESVONC stream, Toulouse, France

 

March 2010 Update for Canine and Feline Lymphoma. 2.5 hours.

Auckland, Rotorua, Wellington, Christchurch.

Gribbles Pathology New Zealand

 

June 2009 ACVIM Oncology: Clinical Workshop. 4 hours.

Moore AS, Frimberger AE. Getting the Most from Your Tumor Histopathology Report.

Frimberger AE, Moore AS. Hematology Monitoring For Small Animal Cancer Patients.

Frimberger AE, Moore AS. Serum Biochemistry Analysis & Urinalysis in Small Animal Cancer Patients.

Moore AS, Frimberger AE. Ancillary Laboratory Testing In Small Animal Cancer Patients.

 

Nov 2009 Getting the most from your tumour histopathology: a user’s guide 1.5 hours.

Adelaide, South Australia.

Gribbles Pathology South Australia

 

June 2009 Moore AS, Frimberger AE, Sullivan N, Reppas G. Retrospective Evaluation of Prognostic Factors In Dogs With Histiocytic Disease.

27th Annual ACVIM Veterinary Medical Forum, 2009.

 

Oct 2008 Moore AS, Frimberger AE, Sullivan N. Prognosis for dogs with splenic fibrohistiocytic nodules following splenectomy alone or splenectomy plus chemotherapy. Abst p67

Twenty-eighth Annual Conference, Veterinary Cancer Society, 2008.

 

Jul 2008 Invited Lecturer. 1.0 hours Abstract pages 72-85

Australian Society for Veterinary Pathology, Surfers Paradise, Australia

 

Jul 2008 Invited Lecturer. 2.0 hours Abstracts pages 17-19; 45-50.

Science Week, Australian College of Veterinary Scientists, 2008

 

Aug 2007 Oncology Stream Coordinator

Invited Lecturer. 3.0 hours

World Small Animal Veterinary Association Conference, Sydney, Australia

 

June 2007 Managing chemotherapy patients in private practice: practical tips. Abst pp 437-439

Managing chemotherapy patients in private practice: patient management. Abst pp 440-442

Diagnosis and treatment of dogs with mammary cancer. Abst pp 443-445

25th Annual ACVIM Veterinary Medical Forum, 2007.

 

Oct 2006 Invited Lecturer. 3.5 hours

World Small Animal Veterinary Association Conference, Prague, Czechoslovakia

 

Jul 2006 Invited Lecturer. 4.5 hours

American Veterinary Medical Association Conference, Honolulu, HI, USA

 

Sep 2005 Invited Keynote Speaker. 4 hours

European Society of Feline Medicine/SAVAB Feline Congress, Antwerp, Belgium.

 

Jul 2005 Invited Lecturer. Isn’t it just a recipe? Giving chemotherapy to pets: 1.5 hours

Science Week, Australian College of Veterinary Scientists, 2005

Abstract pages 5-10

 

May 2005 Invited Lecturer. 3 hours

World Small Animal Veterinary Association Conference, Mexico City, Mexico.

 

Apr 2005 Invited Lecturer: Cancer Epidemiology in Companion Animals: 1 hour

VMS 8417 Advanced Oncology, University of Missouri-Columbia

 

Mar 2005 Invited Lecturer : Cancer Management in Small Animals: 6 hours

ContinuEd Seminars, Kauai, Hawaii

 

Jan 2005 Invited Keynote Speaker: Mast cell tumors and other talks: 13 hours

Japanese Veterinary Cancer Society, Tokyo, Japan

 

Jul 2004 Invited Lecturer. Recent Advances in Cancer Medicine: 4 hours

Science Week, Australian College of Veterinary Scientists, 2004

Abstracts pages 10-12, 45-46, 74-75

 

Jun 2004 Evolving treatments for lymphoma in dogs. Abst pp 419-420

Twenty-second Annual ACVIM Veterinary Medical Forum, 2004.

 

May 2004 Invited Lecturer. Recent Advances in Feline Medicine: 10 hours

North American Veterinary Conference Post Graduate Institute

 

Feb 2004 Invited keynote speaker : 6 hours

Japanese Society of Clinical Pathology, Tokyo, Japan

 

Jun 2003 Doxorubicin for osteosarcoma treatment in dogs. Abst pp 309-310

Moore AS, Dernell W, Ogilvie GK, Kristal O, Elmslie R, Kitchell B, Susaneck S, Rosenthal R, Kleine MK, Obradovich J, Legendre A, Hahn K, Haddad H, Warren D.

Twenty-first Annual ACVIM Veterinary Medical Forum, 2003.

 

Apr 2003 Invited keynote speaker : 9 hours

State-of-the-art lecture: Advances in the treatment of lymphoma.

British Small Animal Veterinary Association, Birmingham, U.K.

 

Mar 2003 Course leader and participant : 4 hours

Tufts International Oncology Symposium, Nassau, New Providence Island

 

Feb 2003 Invited keynote speaker : 4 hours

Bayer’s III Veterinary Updating Symposium, Mexico City, Mexico

 

Sep 2002 Treatment advances for canine osteosarcoma

Changing treatment for lymphoma in cats

Tufts Animal Expo, 2002. Boston MA.

 

May 2002 Moore AS, Bertone ER. Environmental causes of cancer in cats. Abst pp 425-426

Twentieth Annual ACVIM Veterinary Medical Forum, 2002.

 

Mar 2002 Angiogenesis opportunities in veterinary medicine: overview and vision.

Angiogenesis Foundation Board of Director's Meeting, Cambridge MA.

 

Jan 2002 Advances in treating soft-tissue sarcomas in dogs and cats Abst p 488-489

New treatment strategies for osteosarcoma in dogs Abst p 490-492

New treatment strategies for lymphoma in cats Abst p 493- 494

Streptozotocin for insulinoma Abst p 495

Risk factors for oral squamous cell carcinoma in cats Abst p 496

The North American Veterinary Conference, 2002. Proc. Vol 16

 

Dec 2001 Update on treatment of osteosarcoma in dogs and cats

Mast cell tumors in dogs and cats

Treatment of canine thyroid tumors

Chemotherapy for insulinomas

UC Davis Veterinary Endocrinology and Internal Medicine Seminar, Hawaii.

 

Oct 2001 Injection site sarcomas.

Ogilvie GK, Moore AS. Focus on cats with cancer: 6 hours.

Tufts Animal Expo 2001. Boston MA

 

Aug 2001 Practical chemotherapy for the private practitioner

New treatments for canine lymphoma

Adjuvant chemotherapy for canine osteosarcoma

Treatment of mast cell tumors in dogs

Lectures to practitioners in Nagoya and Kobe, Japan.

 

May 2001 Principles of chemotherapy and drug handling

Treatment of canine and feline lymphoma

Adjuvant chemotherapy for canine osteosarcoma

Treatment of mast cell tumors in dogs and cats

São Paulo State Small Animal Practitioners Meeting. Aguas de Lindoia, Brazil.

 

May 2001 Chemotherapy combinations-altered toxicity and efficacy? Abst pp 455-457

The veterinary technician as part of the cancer treatment team. Abst pp 40-42

Chun RA. Moore AS, Phillips B, Ogilvie GK. Osteosarcoma; panel discussion of controversies in treatment. Abst pp 480-481

Nineteenth Annual ACVIM Veterinary Medical Forum, 2001.

 

Oct 2000 Chemotherapy information: a technician’s role.

What is cancer?

Moore AS, Berg RJ. Osteosarcoma of the appendicular skeleton in dogs.

Tufts Animal Expo 2000. Boston MA

 

May 2000 Haematopoietic tumors in dogs as a research model.

Animal Health Trust, Newmarket. U.K.

 

May 2000 Moore AS, Kintzer P. Insulinoma, recent advances in treatment. Abst pp 447-448

Eighteenth Annual ACVIM Veterinary Medical Forum, 2000.

 

May 2000 Spontaneous tumors in dogs as a research model.

University of Missouri, Columbia MO.

 

Nov 1999 Moore AS, Kintzer P, Ogilvie GK, Brewer WG, Burke C, Fischer J, Henry C, Kitchell BE, Kristal O, Sheafor S, Williams LE. A diuresis protocol for streptozotocin in dogs with pancreatic islet cell tumors.p 69.

Nineteenth Annual Conference, Veterinary Cancer Society, 1999.

 

Jun 1999 Principles of chemotherapy and drug handling

New drugs in veterinary chemotherapy

Treatment of canine lymphoma

Treatment of feline lymphoma

Adjuvant chemotherapy for tumors of the urinary tract

Adjuvant chemotherapy for canine osteosarcoma

Treatment of mast cell tumors in dogs and cats

World Animal Hospital Association; Tokyo, Kyoto, Niigata, Nagoya, Sendai, and Osaka, Japan.

 

Jan 1999 Best protocols for treating lymphoma in dogs Abst p 401-403

Canine osteosarcoma: advances in treatment Abst p 404-405

The North American Veterinary Conference, 1999. Proc. Vol 13

 

Jul 1998 Veterinary Forum: Round table discussion: “Compassionate cancer care”

Am Vet Med Assoc Meeting. Baltimore MD.

 

May 1998 Intermittent-dose vs long-term chemotherapy in canine lymphoma. Abst pp 365-366

Sixteenth Annual ACVIM Veterinary Medical Forum, 1998.

 

Feb 1998 Adjuvant therapy for canine and feline mammary tumors and soft tissue sarcomas

Management of canine and feline lymphoma

Lectures to practitioners, Kourakuen, Asakusa and Kozukue, Japan.

 

Keynote Address: Management of canine and feline mast cell tumors

Adjuvant therapy for soft-tissue sarcomas

Seventh Annual Conference of the Japan Veterinary Cancer Society, Kanagawa, Japan.

Apr 1997 Moore A, Imondi A, L'Heureux D. Preclinical evaluation of three dosage schedules of 9-aminocamptothecin (9-AC) for the treatment of spontaneous lymphoma in dogs.

Abst #503 Vol 38 Proc AACR

88th Annual Meeting American Assoc. Cancer Research, 1997.

 

Apr 1997 Cancer staging and decision-making

Lymphoma

Feline vaccine-associated tumors

Small Animal Oncology Conference, University of Zurich, Switzerland.

 

Oct 1996 Moore AS, Wood CA, Imondi AR, L'Heureux, Cotter SM, Williams L. Oral and intravenous administration of 9-aminocamptothecin to dogs with lymphoma: preliminary findings. Abst p24-25

Sixteenth Annual Conference, Veterinary Cancer Society, 1996.

 

May 1996 Oral and intravenous administration of 9-aminocamptothecin to dogs with lymphoma: preliminary findings.

Pharmacia & Upjohn 9-AC Workshop, Philadelphia PA, 1996.

 

May 1996 New agents for the treatment of relapsing canine lymphoma. Abst p 210-211

Pesticides and environmental carcinogenesis. Abst p 620

Fourteenth Annual Veterinary Medical Forum. ACVIM, 1996.

 

Feb 1996 Abdominal tumors

Feline lymphoma

Skin tumors

Mast cell tumors

Western States Veterinary Conference, 68th Annual Conference, 1996.

 

Oct 1995 Invited Participant: Paradigms in cancer biology and cancer therapy.

Krasnow Institute for Advanced Study; George Mason University, Airlie, VA, 1995

 

Oct 1995 Moore AS, London CA, Wood CA, Frimberger AE, Cotter SM, L'Heureux DA. Preliminary report on the use of lomustine (CCNU) for the treatment of relapsed lymphoma in dogs. Abst p 39-40

Fifteenth Annual Conference, Veterinary Cancer Society, 1995.

 

Oct 1994 Moore AS, Frimberger AE, L'Heureux DA, Cotter SM. Doxorubicin vs COP for maintenance of remission in feline lymphoma. Abst p 42

Fourteenth Annual Conference, Veterinary Cancer Society, 1994.

 

May 1994 Feline lymphoma, treatment and prognosis. Abst p 278-280

Twelfth Annual Veterinary Medical Forum. ACVIM, 1994.

 

Feb 1994 Course Director: Treatment of cancer in Companion Animals.

Postgraduate Committee in Veterinary Science, Sydney, Australia, 1994.

 

Oct 1993 Moore AS, Ruslander D, L'Heureux D, Cotter SM. Oral idarubicin for `maintenance' therapy of feline lymphoma. Abst p 86-87

Thirteenth Annual Conference, Veterinary Cancer Society, 1993.

 

Jul 1993 Moore AS, Leveille CR, Reimann KA, Arias IM. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Abst 66

XVI Symposium of the International Association for Comparative Research on Leukemia and Related Diseases, 1993.

 

Oct 1992 Moore AS, Leveille CR, Reimann KA, Shu H, Arias IM. The expression of P-glycoprotein in canine lymphoma and its association with multidrug resistance. Abst p 10-11

Twelfth Annual Conference, Veterinary Cancer Society, 1992.

 

Oct 1991 Moore AS, Cotter SM, Ruslander D, L'Heureux D. Interim analysis of the toxicoses and efficacy associated with Idarubicin administration in cats with malignant tumors. Abst p 102-103

Moore AS, Ogilvie GK, Ruslander D, Cotter SM, Berg RJ, L'Heureux D. Mitoxantrone for the therapy of canine lymphoma. Abst p 3-4

Eleventh Annual Conference, Veterinary Cancer Society, 1991.

 

Jun 1991 Intracavitary Chemotherapy in dogs. Abst p721-723

Ninth Annual Veterinary Medical Forum. ACVIM, 1991.

 

Nov 1990 Moore AS, Ogilvie GK, Obradovich JE, Elmslie RE, Vail DM, Dickinson K, Walters L, Klein MK, Peaston A, Straw RC, Withrow SJ. Interim analysis of a study to determine the toxicoses and efficacy associated with the administration of mitoxantrone to cats with malignant tumors. Abst p 9-10

Tenth Annual Conference, Veterinary Cancer Society, 1990.

 

Oct 1989 Moore AS, Kirk C, Cardona A. Intracavitary cisplatin chemotherapy: experience with six dogs. Abst p 10-11

Ninth Annual Conference, Veterinary Cancer Society, 1989.

 

Oct 1988 Moore AS, Ogilvie GK, Curtis CR. Evaluation of cisplatin induced emesis in 115 dogs with malignant neoplasia. Abst p 13

Moore AS, Cardona A, Madewell BR. Cisplatin for treatment of transitional cell carcinoma of the urinary bladder and urethra - a study of 14 dogs. Abst p 24

Eighth Annual Conference, Veterinary Cancer Society, 1988

 

May 1988 Moore AS, Newell A, Madewell B, Marafino B, Rudolph A, Kopplin J, Theilen G. A preclinical trial of recombinant tumor necrosis factor (rhTNF) plus recombinant interleukin-2 (rhIL2) in naturally occurring canine malignancies. Abst 1438 Vol 29 Proc AACR

79th Annual Meeting American Assoc. for Cancer Research, 1988.

 

Oct 1987 Moore AS, Madewell BR, Lund J; Immuno-histochemical evaluation of intermediate filament expression in canine and feline neoplasms. Abst p 31

Moore AS, Theilen GH, Madewell BR, Carrie KL, Newell AD. A study of the combined toxicities of tumor necrosis factor (TNF) and interleukin 2 (IL2) in dogs with spontaneously occurring neoplasms. Abst p 31-32

Seventh Annual Conference Veterinary Cancer Society, 1987.

 

Aug 1985 Moore AS. The role of the Ames seralyzer in a small animal veterinary practice.

XXII World Veterinary Congress, Perth, Australia.

AWARDS AND HONORS

 

The International Society of Feline Medicine Award for Outstanding Contribution to Feline Medicine 2010

Honorary Membership Award from Australian College of Veterinary Scientists Chapter of Veterinary Pharmacology 2005

Honorary Membership of the Japan Veterinary Cancer Society. 1998

Tufts University Outstanding Faculty Award. 1997.

MSD AGVET Award for Creativity in Teaching. 1996. "Pet Loss Support Hotline Selective/Elective"

Dr. Robert S Brodey Clinical Research Award, Veterinary Cancer Society, 1988.

Lionel Lonsdale Clinical Fellowship, University of Sydney 1981.

About Us

We're all about providing the best possible quality of life for pet animals with cancer and their human families.

More about us

For Veterinarians

Information, conversion charts and templates to help you manage treatment in your patients.

Read more

For Pet Owners

We understand how difficult it can be to have a pet diagnosed with cancer so we've put together some answers to common questions.

Read more

Get in touch

Veterinary Oncology Consultants
379 Lake Innes Drive
Lake Innes, NSW 2446
Australia

voc@vetoncologyconsults.com

+61 (2) 6585 3192